Description: The respiratory care devices market is projected to grow from $24.16 billion in 2024 to $49.19 billion by 2033, at a CAGR of 8.22%. The rise is fueled by increasing cases of respiratory diseases such as asthma, COPD, and sleep apnea. Key devices include nebulizers, inhalers, CPAP machines, and ventilators, crucial for therapy and patient monitoring. Top players like Medtronic, Philips, GE Healthcare, and others are driving innovation. Sustainability efforts are notable among companies like Baxte

Description: Wondering if Baxter International is a hidden gem or a value trap? You're not alone, especially with the stock catching the eye of investors searching for a bargain. Despite a tough market stretch with a 20.1% dip over the past month and a dramatic 37.4% drop year-to-date, many are asking whether the risk has actually created new upside. In recent weeks, headlines have focused on Baxter's strategic moves, including updates around divestitures and streamlining its business operations. These...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Stephen Rusckowski to Oracle's Board of Directors and increased the size of the Board to 14. The election is effective as of November 18, 2025.

Description: DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth i

Description: DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured note

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.

Description: Baxter International Inc. (NYSE:BAX) is among the 13 Most Undervalued Stocks Under $20 to Buy. On October 31, Argus Research downgraded its rating of the stock to Hold from Buy. The adjustment followed the company’s third-quarter fiscal 2025 earnings call a day prior, in which it announced a significant reduction to its quarterly dividend to […]

Description: Baxter International (BAX) has drawn investor attention after posting third quarter results that showed higher sales but a net loss year over year. The company also provided updated guidance calling for moderate sales growth into 2025. See our latest analysis for Baxter International. The latest string of updates from Baxter International, including a modest dividend announcement and confirmation of moderate forward guidance, have not reversed its negative momentum. Even with a small lift in...

Description: DEERFIELD, Ill., November 11, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock.

Description: The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic

Description: DEERFIELD, Ill., November 07, 2025--The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the continuation of a partnership with Northwestern University’s School of Education and Social Policy (SESP) to provide science, technology, engineering and math (STEM) programs for students and teachers throughout the Chicagoland area. Supported by a three-year $2.6 million grant from the Foundation, the Baxter Center for Science Edu

Description: Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance shortfalls primarily to ongoing challenges in its Infusion Therapies & Technologies division, which faced a continued pause on Novum IQ Large Volume pump shipments, and to softness in U.S. demand for IV solutions. CEO Andrew Hider candidly stated, “We are not satisfied with our current performance,” emph

Description: Baxter International’s consensus analyst price target has seen a sharp decline recently, dropping from $28.00 per share to $24.07 per share. This reduction highlights a shift in sentiment, as it stems from mixed expectations about the company’s ability to overcome operational headwinds and sustain long-term growth. Stay tuned to discover how investors and observers can stay informed as the story around Baxter International’s outlook continues to evolve. Stay updated as the Fair Value for...

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: As Baxter International has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Description: Shares of healthcare company Baxter International (NYSE:BAX) fell 2.9% in the afternoon session after the stock continued to fall as the company reported mixed third-quarter results, lowered its full-year guidance, and announced a plan to reduce its dividend. While adjusted earnings per share of $0.69 beat expectations, revenue of $2.84 billion fell short of forecasts. The positive earnings were overshadowed by several concerns. The company's gross margin plunged due to product mix shifts and hi

Description: Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.

Description: The company's mixed quarterly results and uninspiring guidance led to a sell-off.

Description: Baxter International Inc (BAX) reports a 41% increase in adjusted EPS despite facing headwinds in its Infusion Therapies and Technologies division.

Description: Baxter International recently reported a third-quarter net loss of US$46 million despite year-on-year sales growth, with results shaped by ongoing legal and product safety challenges. Multiple class action lawsuits have been filed in response to defects and serious patient incidents involving the Novum IQ Large Volume Pump, raising concerns about safety controls and corporate disclosure practices. We will assess how these legal and product safety setbacks are now influencing Baxter...

Description: Shares of healthcare company Baxter International (NYSE:BAX) fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.

Description: While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Description: Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.

Description: Baxter (BAX) delivered earnings and revenue surprises of +15.00% and -1.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The Deerfield, Illinois-based company said it had a loss of 9 cents per share. Earnings, adjusted for one-time gains and costs, were 69 cents per share. The results topped Wall Street expectations.

Description: DEERFIELD, Ill., October 30, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.

Description: Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market hours. Here’s what investors should know.

Description: Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.

Description: Baxter International is slated to report its third-quarter earnings this week, with analysts expecting a low double-digit decline in profit amid ongoing industry and macroeconomic headwinds.

Description: Baxter International (BAX) shares have seen modest moves lately, catching the eye of investors interested in value after a challenging year for the stock. Recent returns suggest a mixed sentiment. This creates an interesting setup for those watching healthcare names. See our latest analysis for Baxter International. While Baxter International’s share price has bounced slightly in the last month, a steep drop in the past quarter leaves sentiment on shaky ground. With a 1-year total shareholder...

Description: Chris Barry, group president of medsurg at Solventum, is leaving the company at the end of the year in connection with Knight’s arrival.

Description: Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson.